

PRESS RELEASE

AMORFIX LIFE SCIENCES LTD. (formerly Luxor Developments Inc.)

September 21, 2005

Trade Symbol: AMF

NR #05/1

LUXOR/AMORFIX COMPLETE AMALGAMATION AND FINANCING

September 21, 2005 (Toronto, Ontario). Luxor Developments Inc. is pleased to announce that today it completed an amalgamation with Amorfix Life Sciences Ltd. The amalgamated company will continue under the Amorfix name. Having previously received conditional TSX-V approval for this amalgamation and related transactions (see news release of August 31, 2005), the amalgamated company hopes to begin trading under the Amorfix name and new trade symbol, AMF, sometime around the beginning of October. Prior to returning to trade, the amalgamated company must complete its filings with the TSX-V as required in order to satisfy the conditions in the TSX-V's conditional approval letter. Once the company completes this filing and confirms with the TSX-V the date it will return to trade, it will issue a news release to confirm same.

The completion of the amalgamation also triggers the release of the financing funds of \$3,000,000 which were being held in trust pending shareholder approval for the amalgamation. The funds will be released to the company to be used for the further development of its business. The financing was lead by First Associates in Calgary, Alberta.

The amalgamation was approved by the shareholders of both Luxor and Amorfix at shareholder meetings each held on September 20, 2005. At the Luxor meeting, the shareholders also approved the appointment of a new Board for the amalgamated company. The new board consists of the following individuals, who take office immediately:

- Dr. Don Rix
- Graham Strachan
- Don McCaffrey
- Dr. George Adams, President and CEO
- Dr. Neil Cashman, CSO and Founder

The new management team of the amalgamated company consists of the following individuals:

- Dr. George Adams, President, CEO and Director
- Dr. Neil Cashman, CSO, Founder and Director
- James Parsons, CFO
- Vigen Nazarian, Director, Business Development and Founder
- David Raffa, Director, Corporate Finance and Founder
- Dr. Joachim Ostermann, Director of R&D and Founder

- Dr. Marty Lehto, Senior Scientist and Founder

The biographies of the Directors and the management team are summarized in the aforementioned news release of August 31, 2005, and are described in detail in the joint Information Circular prepared by the companies for the shareholders' meetings. The joint Information Circular is available to any member of the public on SEDAR.

The new management team would like to take this opportunity to thank the principals of Luxor and, in particular, Roger Kotch and Mike Halverson, as well as Owen Pinnell and Bob Dittmer of i3 Capital Partners Inc., for their invaluable assistance in getting this transaction done.

The amalgamated company has a total of 23,950,000 common shares issued and outstanding and 4,225,000 warrants to acquire additional common shares. In addition, the shareholders approved a Stock Option Plan reserving up to a total of 4,000,000 common shares for future stock options. The company has not yet granted any stock options pursuant to the Stock Option Plan but anticipates doing so shortly. Full particulars of the terms of the warrants are contained in the Information Circular referred to above.

Amorfix is an emerging theranostics company focused on the diagnosis and treatment of neurodegenerative diseases, where aggregated misfolded proteins (AMPs) are prevalent. These include aggregated misfolded prion protein which makes up "prions," the infectious agents of the Transmissible Spongiform Encephalopathies (TSE), such as Bovine Spongiform Encephalopathy (BSE or "mad cow disease") and the human form, variant Creutzfeldt-Jakob Disease (vCJD), as well as degenerative diseases such as Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS) and Parkinson's Disease (PD). The company was formed in January 2004 to commercialize the discoveries of the epitope protection (EP) technologies at the University of Toronto discovered by Drs. Neil Cashman and Marty Lehto. These discoveries position the company to become the world authority on AMP diseases. The company will use this new knowledge to develop diagnostic kits, therapeutics and prophylactics for AMP diseases.

The company has established a laboratory in Toronto and received all approvals for a containment facility to allow it to test prion-containing animal samples and blood. It has further developed its technology to mask the normal prion protein without affecting the prions. With this improved selectivity, the company is on schedule to finish the development of a blood screening test for infectious vCJD prions, trademarked as EP-vCJD™ and begin the development of its EP-BSE™ test for cattle.

For further information, please contact:

Dr. George Adams, President and CEO
Amorfix Life Sciences Ltd.
416-557-4647

James Parsons, CFO
Amorfix Life Sciences Ltd.
416-705-5686

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Actual future results may differ materially from those contemplated. The risks, uncertainties and other factors that could influence the actual results are described in documents filed with regulatory authorities.